By Anthony O. Goriainoff


Hikma Pharmaceuticals PLC said Wednesday that it has resumed the launch of its generic version of GlaxoSmithKline PLC's asthma treatment, Advair Diskus, in the U.S.

The FTSE 100 pharmaceutical company said the move followed the Food and Drug Administration's approval of the amendment to its abbreviated new drug application, submitted in January. The change reflected enhanced packaging controls required to meet industry standards adopted since the time of the initial submission.


Write to Anthony O. Goriainoff at


(END) Dow Jones Newswires

April 21, 2021 02:31 ET (06:31 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.